Up a level |
Raz, Itamar, Mosenzon, Ofri, Bonaca, Marc P, Cahn, Avivit, Kato, Eri T, Silverman, Michael G, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404 et al (show 5 more authors)
(2018)
DECLARE-TIMI 58: Participants' baseline characteristics.
DIABETES OBESITY & METABOLISM, 20 (5).
pp. 1102-1110.
Kato, Eri T, Silverman, Michael G, Mosenzon, Ofri, Zelniker, Thomas A, Cahn, Avivit, Furtado, Remo HM, Kuder, Julia, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A et al (show 13 more authors)
(2019)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
CIRCULATION, 139 (22).
pp. 2528-2536.
Wiviott, Stephen D, Raz, Itamar, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Silverman, Michael G, Bansilal, Sameer, Bhatt, Deepak L, Leiter, Lawrence A et al (show 6 more authors)
(2018)
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
AMERICAN HEART JOURNAL, 200.
pp. 83-89.